Novartis AG ADR (NVS)vsSilence Therapeutics PLC (SLN)

NVS

Novartis AG ADR

NYSE

$147.85

+3.44%

HEALTHCARE · Cap: $282.11B

SLN

Silence Therapeutics PLC

NASDAQ

$7.31

+2.81%

HEALTHCARE · Cap: $363.70M

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 10121188% more annual revenue ($56.58B vs $559,000). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5

Piotroski: 4/9Altman Z: 1.96

SLN

Avoid

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 5.0

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Intrinsic value data unavailable for SLN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability

23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

SLN0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

NVS4 concerns · Avg: 3.0/10

PEG RatioValuation

2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth

-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth

-9.3%2/10

Earnings declined 9.3%

SLN4 concerns · Avg: 3.0/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$363.70M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Return on EquityProfitability

-90.3%2/10

ROE of -90.3% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : SLN

SLN has a balanced fundamental profile.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Bear Case : SLN

The primary concerns for SLN are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

NVS profiles as a declining stock while SLN is a value play — different risk/reward profiles.

SLN carries more volatility with a beta of 1.33 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 17/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other rare and metabolic indications. The company is headquartered in London, the United Kingdom.

Compare with Other DRUG MANUFACTURERS - GENERAL Stocks

NVS vs LLY NVS vs JNJ NVS vs ABBV NVS vs AZN NVS vs MRK SLN vs LLY SLN vs JNJ SLN vs ABBV SLN vs AZN SLN vs MRK

Want to dig deeper into these stocks?

Full NVS Analysis →Full SLN Analysis →